NCT03416491 - Safety and Efficacy of KW-136 and Sofosbuvir for Treatment of Chronic Hepatitis C | Biotech Hunter

Enrollment

110

Participants

Timeline

Start Date

February 15, 2017

Primary Completion Date

September 17, 2017

Study Completion Date

November 8, 2017

Conditions

Hepatitis C, Chronic

Interventions

DRUG

KW-136

KW-136 30 mg was provided in 3 capsules, 10 mg each, and KW-136 60 mg in a single capsule of 60 mg.

DRUG

Sofosbuvir

Sofosbuvir was provided in a single tablet of 400 mg.

Trial Locations (12)

100044

Peking University People's Hospital, Beijing

100050

Capital Medical University Affiliated Beijing Youyi Hospital, Beijing

100069

Capital Medical University Affiliated Beijing You'an Hospital, Beijing

110006

Shenyang Municipal Sixth People's Hospital, Shenyang

130021

Jilin University First Hospital, Changchun

210003

Nanjing Municipal Second Hospital, Nanjing

250021

Ji'nan Municipal Hospital of Infectious Disease, Ji'nan

266011

Qingdao Municipal Hospital, Qingdao

400038

Chinese PLA Third Military Medical University First Affiliated Hospital, Chongqing

450015

He'nan Provincial Hospital of Infectious Disease (Zhengzhou Municipal Sixth People's Hospital), Zhengzhou

Dalian Municipal Sixth People's Hospital, Dalian

510060

Guangzhou Municipal Eighth People's Hospital, Guanzhou

All Listed Sponsors

collaborator

KawinGreen Biotech Co., Ltd.

UNKNOWN

lead

Kawin Technology Share-holding Co., Ltd.

INDUSTRY